. Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective. JAMA Intern Med. 2021 Oct 1;181(10):1276-1278. PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. Lecanemab Follows Aduhelm’s Path to Accelerated Approval